Is the ‘serious’ factor in germline modification really relevant? A response to Kleiderman, Ravitsky and Knoppers
Journal of Medical Ethics 46 (2):151-152 (2020)
AbstractShould we use human germline genome modification only when serious diseases are involved? This belief is the underlying factor in the article written by Kleiderman, Ravitsky and Knoppers to which I now respond. In my opinion, the answer to this question should be negative. In this paper, I attempt to show that there are no good reasons to think that this technology should be limited to serious diseases once it is sufficiently proven to be safe and efficient. In fact, opting otherwise would negatively harm human beings’ right to the highest standard of health that unmodified embryos could promote. Therefore, the issue should not be so much to define adequately what a serious disease is, but rather to elucidate whether this concept should play any role beyond the context of preimplantation genetic testing. This paper argues that we should not accept the similarity between technologies such as PGT and HGGM because they face different challenges and offer totally different possibilities. Therefore, we are in urgent need to build a completely new ethical architecture that covers the application of germline editing in human embryos. As a part of that process, a much deeper debate on the necessity of distinguishing different disease types is required.
Added to PP
Historical graph of downloads
Citations of this work
‘Serious’ Factor—a Relevant Starting Point for Further Debate: A Response.Erika Kleiderman, Vardit Ravitsky & Bartha Maria Knoppers - 2020 - Journal of Medical Ethics 46 (2):153-155.
Similar books and articles
The ‘Serious’ Factor in Germline Modification.Erika Kleiderman, Vardit Ravitsky & Bartha Maria Knoppers - 2019 - Journal of Medical Ethics 45 (8):508-513.
Human germline editing: a historical perspective.Michel Morange - 2017 - History and Philosophy of the Life Sciences 39 (4):34.
In Genes We Trust: Germline Engineering, Eugenics, and the Future of the Human Genome.Russell Powell - 2015 - Journal of Medicine and Philosophy 40 (6):669-695.
Islamic Perspectives on CRISPR/Cas9-Mediated Human Germline Gene Editing: A Preliminary Discussion.Noor Munirah Isa, Nurul Atiqah Zulkifli & Saadan Man - 2020 - Science and Engineering Ethics 26 (1):309-323.
Germline Genome Editing Versus Preimplantation Genetic Diagnosis: Is There a Case in Favour of Germline Interventions?Robert Ranisch - 2020 - Bioethics 34 (1):60-69.
Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework.Niklaus H. Evitt, Shamik Mascharak & Russ B. Altman - 2015 - American Journal of Bioethics 15 (12):25-29.
Human Genetic Technology, Eugenics, and Social Justice.W. Malcolm Byrnes - 2001 - The National Catholic Bioethics Quarterly 1 (4):555-581.
Intergenerational Monitoring in Clinical Trials of Germline Gene Editing.Bryan Cwik - 2020 - Journal of Medical Ethics 46 (3):183-187.
CRISPR/Cas9 Genome Editing – New and Old Ethical Issues Arising From a Revolutionary Technology.Martina Baumann - 2016 - NanoEthics 10 (2):139-159.
The Ecological Imperative and its Application to Ethical Issues in Human Genetic Technology.W. Malcolm Byrnes - 2003 - Ethics in Science and Environmental Politics 2003:63-65.
Shaping Individuality: Human Inheritable Germ Line Gene Modification.Maurizio Salvi - 2001 - Theoretical Medicine and Bioethics 22 (6):527-542.
Debating Ethical Issues in Genome Editing Technology.Renzong Qiu - 2016 - Asian Bioethics Review 8 (4):307-326.
"Playing God" and Germline Intervention.Ted Peters - 1995 - Journal of Medicine and Philosophy 20 (4):365-386.
Returning Incidental Findings From Genetic Research to Children: Views of Parents of Children Affected by Rare Diseases.Erika Kleiderman, Bartha Maria Knoppers, Conrad V. Fernandez, Kym M. Boycott, Gail Ouellette, Durhane Wong-Rieger, Shelin Adam, Julie Richer & Denise Avard - 2014 - Journal of Medical Ethics 40 (10):691-696.
The Wisdom of Germline Editing: An Ethical Analysis of the Use of CRISPR-Cas9 to Edit Human Embryos.Jennifer M. Gumer - 2019 - The New Bioethics 25 (2):137-152.